Nurix Therapeutics Says David Lacey Steps Down From Chair Role And Will Remain Board Member And Retain Committee Leadership Roles; Current Board Member Julia Gregory Elected New Board Chair
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics announced that David Lacey has stepped down from his role as Chair but will remain a board member and retain his committee leadership roles. Julia Gregory, a current board member, has been elected as the new Board Chair.
May 20, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
David Lacey has stepped down as Chair of Nurix Therapeutics but will remain a board member and retain his committee leadership roles. Julia Gregory has been elected as the new Board Chair.
The leadership change at Nurix Therapeutics is significant but not likely to have an immediate impact on the stock price. David Lacey's continued involvement and Julia Gregory's election as Chair suggest stability in governance.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100